J. Goldman & CO LP Prometheus Biosciences, Inc. Call Options Transaction History

J. Goldman & CO LP

  • $3.21 Billion
  • Q3 2024

Call Options

1 transactions
Quarter Operation Price Per call calls change calls Held SEC Form
Q1 2023

May 15, 2023
BUY
$103.46 - $126.29 $2.79 Million - $3.41 Million
27,000 New
27,000 $2.9 Million

Others Institutions Holding RXDX

# of Institutions
2
Shares Held
29.6K
Call Options Held
0
Put Options Held
0
View Full List

About Prometheus Biosciences, Inc.

RXDX Quotes by TradingView
  • Ticker RXDX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 40,904,100
  • Description
  • Prometheus Biosciences, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of novel therapeutics and companion diagnostics products for the treatment of inflammatory bowel diseases (IBD). Its lead product includes PRA023, a humanized IgG1 monoclonal antibody (mAb), which is in Phase IIa clinical trial...
More about RXDX
Track This Portfolio

Track J. Goldman & CO LP Portfolio

Follow J. Goldman & CO LP and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of J. Goldman & CO LP, based on Form 13F filings with the SEC.

News

Stay updated on J. Goldman & CO LP with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email